Intellia Therapeutics Inc. (NTLA) Insider Trading

Last 12 months

Insiders bought $1.4M and sold $2.16M on the open market.

56% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$761k

1 buy · 15 sales

Under a 10b5-1 plan

56%

of the value sold

Insiders who bought / sold

1 / 7

executives and directors

Last open-market buy

Jan 2026

Jan 5, 2026

Get an email when NTLA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 2	Michael P Dube VP, Chief Accounting Officer	SoldNo plan	1,864	$12.43	$23k	2.8%	Form 4
Aug 20 – 21	John M Leonard President and CEO	Sold10b5-1 plan 2 parts	22,675	$12.65 average	$287k	1.8%	Form 4
Jul 22	Edward J Dulac III EVP, Chief Financial Officer	SoldNo plan	8,111	$11.25	$91k	5.2%	Form 4
Jul 2	Edward J Dulac III EVP, Chief Financial Officer	Sold10b5-1 plan	4,677	$18.00	$84k	2.9%	Form 4
Jul 1	Michael P Dube VP, Chief Accounting Officer	SoldNo plan	2,641	$16.78	$44k	3.8%	Form 4
Mar 2	James Basta EVP, General Counsel	SoldNo plan	1,211	$13.78	$17k	0.8%	Form 4
Mar 2	Eliana Clark EVP, Chief Technical Officer	SoldNo plan	607	$13.78	$8k	0.6%	Form 4
Jan 5	John M Leonard President and CEO	SoldNo plan	34,146	$9.21	$314k	3.1%	Form 4
Jan 5	Birgit C Schultes EVP, Chief Scientific Officer	SoldNo plan	8,508	$9.21	$78k	7.9%	Form 4
Jan 5	James Basta EVP, General Counsel	SoldNo plan	10,397	$9.21	$96k	9.3%	Form 4
Jan 5	Fred E Cohen Director	Bought	150,000	$9.35	$1.4M	261%	Form 4
Jan 5	David Lebwohl EVP, Chief Medical Officer	SoldNo plan	11,903	$9.21	$110k	8.9%	Form 4
Jan 5	Eliana Clark EVP, Chief Technical Officer	SoldNo plan	9,515	$9.21	$88k	9.8%	Form 4
Jan 5	Edward J Dulac III EVP, Chief Financial Officer	SoldNo plan	6,379	$9.21	$59k	6.0%	Form 4
Jan 5	Michael P Dube VP, Chief Accounting Officer	SoldNo plan	2,989	$9.21	$28k	5.4%	Form 4
Dec 11, 2025	John M Leonard President and CEO	Sold10b5-1 plan 3 parts	88,146	$9.49 average	$836k	7.4%	Form 4
Oct 1, 2025	Birgit C Schultes EVP, Chief Scientific Officer	SoldNo plan	31	$17.38	$539	<0.1%	Form 4
Oct 1, 2025	Michael P Dube VP, Chief Accounting Officer	SoldNo plan	1,871	$17.38	$33k	3.3%	Form 4
Aug 20, 2025	William J Chase Director	Bought	100,000	$10.03	$1M	288%	Form 4
Jul 23, 2025	Edward J Dulac III EVP, Chief Financial Officer	SoldNo plan	7,462	$14.02	$105k	6.6%	Form 4
Jul 2, 2025	Michael P Dube VP, Chief Accounting Officer	SoldNo plan	2,503	$9.95	$25k	4.2%	Form 4
Jul 1, 2025	Eliana Clark EVP, Chief Technical Officer	SoldNo plan	1,022	$9.82	$10k	1.1%	Form 4
Jun 30, 2025 – Jul 1, 2025	Jesse Goodman Director	Sold10b5-1 plan 2 parts	3,094	$9.40 average	$29k	11%	Form 4
Apr 29, 2025	Muna Bhanji Director	Sold10b5-1 plan	265	$8.50	$2k	1.4%	Form 4
Mar 4, 2025	Eliana Clark EVP, Chief Technical Officer	SoldNo plan	679	$8.99	$6k	0.7%	Form 4
Mar 4, 2025	James Basta EVP, General Counsel	SoldNo plan	2,572	$8.99	$23k	2.2%	Form 4
Jan 29, 2025	Muna Bhanji Director	Sold10b5-1 plan	265	$9.97	$3k	1.3%	Form 4
Jan 3, 2025	Michael P Dube VP, Chief Accounting Officer	SoldNo plan	1,372	$12.18	$17k	2.9%	Form 4
Jan 3, 2025	James Basta EVP, General Counsel	SoldNo plan	7,074	$12.18	$86k	8.7%	Form 4
Jan 3, 2025	David Lebwohl EVP, Chief Medical Officer	SoldNo plan	9,557	$12.18	$116k	9.8%	Form 4
Jan 3, 2025	Derek Hicks EVP, Chief Business Officer	SoldNo plan	6,502	$12.18	$79k	9.8%	Form 4
Jan 3, 2025	John M Leonard President and CEO	SoldNo plan	26,807	$12.18	$327k	2.6%	Form 4
Jan 3, 2025	Laura Sepp-Lorenzino EVP, Chief Scientific Officer	SoldNo plan	8,966	$12.18	$109k	10%	Form 4
Jan 2, 2025 – Jan 3, 2025	Eliana Clark EVP, Chief Technical Officer	SoldNo plan 2 parts	7,978	$12.17 average	$97k	11%	Form 4

Oct 2No plan
Michael P Dube
VP, Chief Accounting Officer · sold 1,864 at $12.43
$23k
2.8% of stake
Aug 20 – 2110b5-1 plan
John M Leonard
President and CEO · sold 22,675 at avg $12.65
$287k
1.8% of stake
Jul 22No plan
Edward J Dulac III
EVP, Chief Financial Officer · sold 8,111 at $11.25
$91k
5.2% of stake
Jul 210b5-1 plan
Edward J Dulac III
EVP, Chief Financial Officer · sold 4,677 at $18.00
$84k
2.9% of stake
Jul 1No plan
Michael P Dube
VP, Chief Accounting Officer · sold 2,641 at $16.78
$44k
3.8% of stake
Mar 2No plan
James Basta
EVP, General Counsel · sold 1,211 at $13.78
$17k
0.8% of stake
Mar 2No plan
Eliana Clark
EVP, Chief Technical Officer · sold 607 at $13.78
$8k
0.6% of stake
Jan 5No plan
John M Leonard
President and CEO · sold 34,146 at $9.21
$314k
3.1% of stake
Jan 5No plan
Birgit C Schultes
EVP, Chief Scientific Officer · sold 8,508 at $9.21
$78k
7.9% of stake
Jan 5No plan
James Basta
EVP, General Counsel · sold 10,397 at $9.21
$96k
9.3% of stake
Jan 5
Fred E Cohen
Director · bought 150,000 at $9.35
$1.4M
261% of stake
Jan 5No plan
David Lebwohl
EVP, Chief Medical Officer · sold 11,903 at $9.21
$110k
8.9% of stake
Jan 5No plan
Eliana Clark
EVP, Chief Technical Officer · sold 9,515 at $9.21
$88k
9.8% of stake
Jan 5No plan
Edward J Dulac III
EVP, Chief Financial Officer · sold 6,379 at $9.21
$59k
6.0% of stake
Jan 5No plan
Michael P Dube
VP, Chief Accounting Officer · sold 2,989 at $9.21
$28k
5.4% of stake
Dec 11, 202510b5-1 plan
John M Leonard
President and CEO · sold 88,146 at avg $9.49
$836k
7.4% of stake
Oct 1, 2025No plan
Birgit C Schultes
EVP, Chief Scientific Officer · sold 31 at $17.38
$539
<0.1% of stake
Oct 1, 2025No plan
Michael P Dube
VP, Chief Accounting Officer · sold 1,871 at $17.38
$33k
3.3% of stake
Aug 20, 2025
William J Chase
Director · bought 100,000 at $10.03
$1M
288% of stake
Jul 23, 2025No plan
Edward J Dulac III
EVP, Chief Financial Officer · sold 7,462 at $14.02
$105k
6.6% of stake
Jul 2, 2025No plan
Michael P Dube
VP, Chief Accounting Officer · sold 2,503 at $9.95
$25k
4.2% of stake
Jul 1, 2025No plan
Eliana Clark
EVP, Chief Technical Officer · sold 1,022 at $9.82
$10k
1.1% of stake
Jun 30, 2025 – Jul 1, 202510b5-1 plan
Jesse Goodman
Director · sold 3,094 at avg $9.40
$29k
11% of stake
Apr 29, 202510b5-1 plan
Muna Bhanji
Director · sold 265 at $8.50
$2k
1.4% of stake
Mar 4, 2025No plan
Eliana Clark
EVP, Chief Technical Officer · sold 679 at $8.99
$6k
0.7% of stake
Mar 4, 2025No plan
James Basta
EVP, General Counsel · sold 2,572 at $8.99
$23k
2.2% of stake
Jan 29, 202510b5-1 plan
Muna Bhanji
Director · sold 265 at $9.97
$3k
1.3% of stake
Jan 3, 2025No plan
Michael P Dube
VP, Chief Accounting Officer · sold 1,372 at $12.18
$17k
2.9% of stake
Jan 3, 2025No plan
James Basta
EVP, General Counsel · sold 7,074 at $12.18
$86k
8.7% of stake
Jan 3, 2025No plan
David Lebwohl
EVP, Chief Medical Officer · sold 9,557 at $12.18
$116k
9.8% of stake
Jan 3, 2025No plan
Derek Hicks
EVP, Chief Business Officer · sold 6,502 at $12.18
$79k
9.8% of stake
Jan 3, 2025No plan
John M Leonard
President and CEO · sold 26,807 at $12.18
$327k
2.6% of stake
Jan 3, 2025No plan
Laura Sepp-Lorenzino
EVP, Chief Scientific Officer · sold 8,966 at $12.18
$109k
10% of stake
Jan 2, 2025 – Jan 3, 2025No plan
Eliana Clark
EVP, Chief Technical Officer · sold 7,978 at avg $12.17
$97k
11% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NTLA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: In Vitro & In Vivo Diagnostic Substances

TKNOAlpha Teknova, Inc.

ICCCImmuCell Corporation

NNNNAnbio Biotechnology Ltd

CSBRChampions Oncology, Inc.

PRTAProthena Corporation plc

SPROSpero Therapeutics Inc.

BCYCBicycle Therapeutics PLC

TNGXTango Therapeutics Inc.

Spot a number that looks wrong? Check it in NTLA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NTLA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.